Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6272726 | 0.92 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8522266 | 0.90 | ADORA2B (0.51) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4384737 | 0.89 | ADORA2B (0.53) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6272293 | 0.89 | ADORA2B (0.53) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8536000 | 0.89 | ADORA2B (0.53) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL874734 | 0.88 | ADORA2A (0.45) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Hydrochloric Acid SCHEMBL258895 | 0.88 | ADORA2B (0.52) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3671337 | 0.85 | PNP (0.37) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9960806 | 0.84 | PNP (0.38) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Acetic Acid SCHEMBL4280715 | 0.84 | ADORA2B (0.48) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-2451823-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451940-A1 | BIOPROCESSING | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451476-A1 | CELL-BASED BIOPROCESSING | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2009155504-A9 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-1017394-B1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6303618-B1 | ADMINISTERING PURINE COMPOUND WHICH INHIBITS CYCLIC DEPENDENT KINASE ACTIVITY FOR THERAPY OF TUMOR OR OTHER CELL PROLIFERATION DISORDER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| WO-1999002162-A9 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RES CAMPAIGN TECH (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, RNGTT, METTL16 | PDE4A 855/4885PDE4B 648/4885PDE4C 321/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | PDE4A 865/4885PDE4B 1069/4885PDE4C 526/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | PDE4A 872/4885PDE4B 808/4885PDE4C 369/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | PDE4A 326/4885PDE4B 236/4885PDE4C 125/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | PDE4A 3118/4885PDE4B 3033/4885PDE4C 1928/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | PDE4A 3610/4885PDE4B 3633/4885PDE4C 1747/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | PDE4A 4545/4885PDE4B 4296/4885PDE4C 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.